- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04334785
Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer
April 3, 2020 updated by: Zhimin Shao, Fudan University
Recently, researchers in America reported a clinical research (Alliance Z1072) which proved that cryo-ablation could be considered as a non-surgical treatment of early-stage breast cancer.
The long term effectiveness and safety of cryo-ablation in early invasive breast cancer is still unknown.
Therefore, this prospective study are designed to evaluate the effectiveness and safety of cryo-ablation in early invasive breast cancer.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
186
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhi-Min Shao
- Phone Number: 086-021-64175590
- Email: zhimingshao@yahoo.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Zhimin Shao
- Phone Number: +86-021-64175590
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
stage 1:
- female
- ≥18 years old
- invasive ductal carcinoma proved by core needle biopsy. Other type of breast cancer should be well considered and decided by investigators. Pathological report should be complete (with the result of ER, PR , HER2, KI67 etc., and FISH report of ERBB2 gene if necessary).
- lump can be detected by ultrasound.
- image results (including ultrasound, mammography and MR image) prove the lump is single-center, the maximum diameter of the lump <2cm.
- with enough breast tissue, and enough space from lump to skin.
- patients is not pregnant and has no plan for pregnancy in 2 years.
- ECOG level: 0-2
- serum creatinine≤1.1 mg/dl
- for patients with double side (left and right side) breast cancer, both side of the tumor should meet the inclusion criteria.
- patients are accessible for the follow up and mentally healthy.
stage 2:
- female
- ≥18 years old
- invasive ductal carcinoma proved by core needle biopsy. Other type of breast cancer should be well considered and decided by investigators. Pathological report should be complete (with the result of ER, PR , HER2, KI67 etc., and FISH report of ERBB2 gene if necessary).
- lump can be detected by ultrasound.
- image results (including ultrasound, mammography and MR image) prove the lump is single-center, the maximum diameter of the lump <1.5cm.
- with enough breast tissue, and enough space from lump to skin.
- clinically N0 before cryo-ablation.
- patients is not pregnant and has no plan for pregnancy in 2 years.
- ECOG level: 0-2
- serum creatinine≤1.1 mg/dl
- for patients with double side (left and right side) breast cancer, both side of the tumor should meet the inclusion criteria.
- patients are accessible for the follow up and mentally healthy.
Exclusion Criteria:
stage 1:
- < 18 years old
- male
- the same side breast of the lump have been treated by surgery or other physical treatment within 3months.
- benign tumor or tumor in situ or tumor in situ with micro-invasion proved by core needle biopsy. Pathological report is not complete (with the result of ER, PR , HER2, KI67 etc., and FISH report of ERBB2 gene if necessary).
- image results (including ultrasound, mammography and MR image) prove the lump is multi-center, the maximum diameter of the lump ≥2cm.
- image results (including ultrasound, mammography) prove calcium region ≥ 5mm
- lump can not be clearly detected by ultrasound. For example, the boundary of tumor is not clear, or the maximum diameter detected by MRI is more than 1.5 times larger than the maximum diameter detected by ultrasound.
- before the endpoint, patients is treated by other local treatment.
- ECOG Level >2
- serum creatinine>1.1 mg/dl
- patients are not accessible for the follow up and mentally unhealthy.
- patients are pregnant or lactating, or have plan for pregnancy in 2 years.
- other situations which make patients not suitable for the trail or cryo-ablation.
stage 2:
- < 18 years old
- male
- the same side breast of the lump have been treated by surgery or other physical treatment within 3months.
- benign tumor or tumor in situ or tumor in situ with micro-invasion proved by core needle biopsy. Pathological report is not complete (with the result of ER, PR , HER2, KI67 etc., and FISH report of ERBB2 gene if necessary).
- absolute contraindication for breast conserving surgery.
- image results (including ultrasound, mammography and MR image) prove the lump is multi-center, the maximum diameter of the lump ≥1.5cm.
- image results (including ultrasound, mammography) prove calcium region ≥ 5mm
- lump can not be clearly detected by ultrasound. For example, the boundary of tumor is not clear, or the maximum diameter detected by MRI is more than 1.5 times larger than the maximum diameter detected by ultrasound.
- NOT clinically N0 before cryo-ablation.
- patients are treated after neoadjuvant chemotherapy or neoadjuvant endocrine therapy.
- patients with advanced breast cancer or other type of cancers.
- with BRCA1/2 mutation
- before the endpoint, patients is treated by other local treatment.
- ECOG Level >2
- serum creatinine>1.1 mg/dl
- can not finish the radiotherapy afterwards or with contraindication of radiotherapy
- patients are not accessible for the follow up and mentally unhealthy.
- patients are pregnant or lactating, or have plan for pregnancy in 2 years.
- other situations which make patients not suitable for the trail or cryo-ablation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: cryo-ablation group
In the first stage, for patients who meet the criteria, cryo-ablation will be conducted for the lump of invasive breast cancer, and traditional surgery will be conducted within 32days after cryo-surgery.
In the second stage, for patients who meet the criteria, cryo-ablation will be conducted, and 5-year effectiveness and safety will be evaluated subsequently.
|
Under the guide of ultrasound, cryo-ablation for the lump of early invasive breast cancer will be conducted.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stage 1: Effectiveness of cryo-ablation
Time Frame: 1 month
|
In the first stage, patients will receive traditional surgery 1month after the cryo-ablation.
After the traditional surgery (mastectomy or breast conserving surgery), the pathological report will show whether there is tumor tissue left in the breast tissue.
If there is no tumor left in breast, cryo-ablation is effective in eliminating the tumor.
Otherwise, cryo-ablation is ineffective.
|
1 month
|
Stage 2: LRFS(local-regional free survival)
Time Frame: 5 years
|
In the second stage, 5-year local-regional free survival will be evaluated for patients with the treatment of cryo-ablation and traditional surgery is spared.
|
5 years
|
Stage 2: Effectiveness of cryo-ablation (3 months after cryo-ablation)
Time Frame: 3 month
|
In the second stage, patients will receive muti-point core needle biopsy (which collect multi-point tissue from the region which was once the tumor region, as reported by MRI or ultrasound) 3months after the cryo-ablation.
After the multi-point core needle biopsy, the pathological report will show whether there there is tumor tissue left in the breast tissue.
If there is no tumor left in breast, cryo-ablation is effective in eliminating the tumor.
Otherwise, cryo-ablation is ineffective.
|
3 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stage 1: instant success rate
Time Frame: 3 minutes
|
Instant success rate will be evaluated instantly by the surgeon after the cryo-ablation, by his/her own judgement and ultrasound image.
|
3 minutes
|
Stage 1: negative predictive value of ultrasound
Time Frame: 14 days and 28 days
|
In the first stage, ultrasound will be conducted twice on day 14 and day 28 after the cryo-ablation (16 or 2 days before the traditional surgery).
Negative predictive value of ultrasound will be calculated according to the pathological report after the traditional surgery in day 30.
Negative predictive value = number of the patients who is pathologically negative AND ultrasound-negative/ number of patients who is ultrasound-negative
|
14 days and 28 days
|
Stage 1: adverse events
Time Frame: 1 month
|
Short-term safety of cryo-ablation after the treatment
|
1 month
|
Stage 2: instant success rate
Time Frame: 3 minutes
|
Instant success rate will be evaluated instantly by the surgeon after the cryo-ablation, by his/her own judgement and ultrasound image.
|
3 minutes
|
Stage 2: shrinking rate
Time Frame: 5 years
|
Comparing with the baseline tumor size, shrinking rate of the lump will be calculated in 3 months, 6 months, 12 months, 18 months, 2 years, 3 years, 4 years, 5 years after cryo-ablation.
The size of the lump will be evaluated by MR image.
|
5 years
|
Stage 2: adverse events
Time Frame: 5 years
|
Short-term and long-term safety of cryo-ablation after the treatment
|
5 years
|
Stage 2: breast self evaluation
Time Frame: 5 years
|
breast self evaluation for patients with cryo-ablation and for whom traditional surgery is spared, as assessed by BREAST Q© index.
The BREAST-Q has a modular, procedure-specific structure with scales that evaluate both satisfaction and quality of life.
Psychometric evaluation reveals high reliability, validity and responsiveness to surgical intervention across all scales.
Breast Q is composed of aesthetical and emotional modules, and each score ranges from 1 to 4 points (higher values represent a better self evaluation).
By comparing the sum of the score in different modules before and after the surgery, Breast Q can help to facilitate a self evaluation for breast cancer patients.
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Zhi-Min Shao, Fudan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 1, 2020
Primary Completion (Anticipated)
May 1, 2025
Study Completion (Anticipated)
May 1, 2025
Study Registration Dates
First Submitted
March 31, 2020
First Submitted That Met QC Criteria
April 3, 2020
First Posted (Actual)
April 6, 2020
Study Record Updates
Last Update Posted (Actual)
April 6, 2020
Last Update Submitted That Met QC Criteria
April 3, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCHBCC-N024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on cryo-ablation
-
CSA Medical, Inc.WithdrawnRadiation Proctitis | Radiation Induced Proctitis
-
Deutsches Herzzentrum MuenchenCryoCath Technologies Inc.CompletedAtrioventricular Nodal Reentry TachycardiaGermany
-
CSA Medical, Inc.University of MiamiCompletedEsophageal Cancer | Barrett's EsophagusUnited States
-
Sheba Medical CenterMedtronicUnknownPremature Ventricular Contraction
-
CSA Medical, Inc.TerminatedLung Cancer | MesotheliomaUnited States
-
University of Maryland, BaltimoreCSA Medical, Inc.TerminatedEsophageal Neoplasms | Deglutition Disorders | GERD | Barrett Esophagus | NeoplasmUnited States
-
Shaare Zedek Medical CenterMedtronicUnknownHOCM, Hypertrophic Obstructive Cardiomyopathy
-
Jonsson Comprehensive Cancer CenterWithdrawnMesotheliomaUnited States
-
Karolinska University HospitalRecruiting
-
Northwell HealthPhilips HealthcareRecruitingProstate Cancer | Prostate DiseaseUnited States